Bolt Biotherapeutics, Inc. expected to post a loss of $3.39 a share - Earnings Preview
Bolt Biotherapeutics, Inc. <BOLT.OQ> expected to post a loss of $3.39 a share - Earnings Preview
Bolt Biotherapeutics, Inc. BOLT.OQ BOLT.O is expected to show a fall in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2026
The Redwood City California-based company is expected to report a 72.3% decrease in revenue to $500 thousand from $1.8 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Bolt Biotherapeutics, Inc. is for a loss of $3.39 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Bolt Biotherapeutics, Inc. is $7.00, about 72.8% above its last closing price of $4.05
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -2.85 | -2.85 | -4.31 | Missed | -51.2 |
Dec. 31 2026 | -4.39 | -6.11 | -3.84 | Beat | 37.1 |
Sep. 30 2025 | -5.66 | -5.79 | -3.72 | Beat | 35.7 |
Jun. 30 2025 | -6.50 | -6.45 | -4.46 | Beat | 30.9 |
Mar. 31 2025 | -7.14 | -7.25 | -5.80 | Beat | 20 |
Dec. 31 2024 | -7.60 | -7.60 | Met | 0 | |
Sep. 30 2024 | -6.71 | -7.05 | -8.00 | Missed | -13.5 |
Jun. 30 2024 | -10.44 | -9.60 | -9.20 | Beat | 4.2 |
This summary was machine generated August 10 at 11:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)